Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 3, 2007, Pages 215-219

  Su, Andy W ^a   Jani, Ashesh B ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Intensity modulation radiotherapy; Outcomes; Prostate cancer; Radiotherapy; Toxicity

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; HORMONE RECEPTOR BLOCKING AGENT; LEUPRORELIN;

AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; MEDICAL RECORD; PELVIS; PROSTATE CANCER; REGRESSION ANALYSIS; STUDENT T TEST; TREATMENT DURATION; TREATMENT OUTCOME; UROGENITAL SYSTEM; UROGENITAL TRACT DISEASE;

AGED; GASTROINTESTINAL DISEASES; HUMANS; MALE; MALE UROGENITAL DISEASES; PELVIS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY;

EID: 34249980944     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000256705.93441.a0     Document Type: Article

References (31)

1. Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol. 2003;4:233-241.
2. Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet. 2003;361:1045-1053.
3. McLoughlin M, Hazra T, Schirmer HK, et al. Telecobalt therapy for prostatic cancer: rationale, results and future considerations. J Urol. 1975;113:378-379.
4. Pollack A, Zagars GK, Starkschall G, et al. Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys. 1996;34:555-564.
5. Hanks GE. Conformal radiotherapy for prostate cancer. Ann Med. 2000;32:57-63.
6. Teh BS, Amosson CM, Mai WY, et al. Intensity modulated radiation therapy (IMRT) in the management of prostate cancer. Cancer Invest. 2004;22:913-924.
7. Zelefsky MJ, Fuks Z, Leibel SA. Intensity-modulated radiation therapy for prostate cancer. Semin Radiat Oncol. 2002;12:229-237.
8. McGowan DG. The value of extended field radiation therapy in carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1981;7:1333-1339.
9. Asbell SO, Krall JM, Pilepich MV, et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys. 1988;15:1307-1316.
10. Roach M 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904-1911.
11. Zelefsky MJ, Fuks Z, Happersett L, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 2000;55:241-249.
12. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111-1116.
13. Li XA, Wang JZ, Jursinic PA, et al. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2005;61:1251-1257.
14. Gershkevitsh E, Clark CH, Staffurth J, et al. Dose to bone marrow using IMRT techniques in prostate cancer patients. Strahlenther Onkol. 2005; 181:172-178.
15. Ashman JB, Zelefsky MJ, Hunt MS, et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:765-771.
16. Liu L, Glicksman AS, Coachman N, et al. Low acute gastrointestinal and genitourinary toxicities in whole pelvic irradiation of prostate cancer. Int J Radiat Oncol Biol Phys. 1997;38:65-71.
17. Luxton G, Hancock SL, Boyer AL. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2004;59:267-284.
18. Sanguineti G, John B, Frazone P, et al. IMRT to treat the pelvic nodes while escalating the dose to the prostate gland: acute toxicity data in 45 consecutive patients. Int J Radiat Oncol Biol Phys. 2004;60(suppl):466- 467.
19. Jani AB, Su A, Milano MT. Intensity-modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicity. Urology. 2006;67:147-151.
20. Valicenti RK, Winter K, Cox JD, et al. RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? Int J Radiat Oncol Biol Phys. 2003;57:614-620.
21. Ryu JK, Winter K, Michalski JM, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79. 2 Gy). Int J Radiat Oncol Biol Phys. 2002;54:1036-1046.
22. Michalski JM, Winter K, Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys. 2004;58:735-742.
23. Sailer SL, Chaney EL, Rosenman JG, et al. Three dimensional treatment planning at the University of North Carolina at Chapel Hill. Semin Radiat Oncol. 1992;2:267-273.
24. Jani AB, Roeske JC, Rash C. Intensity-modulated radiation therapy for prostate cancer. Clin Prostate Cancer. 2003;2:98-105.
25. Vijayakumar S, Awan A, Karrison T, et al. Acute toxicity during external-beam radiotherapy for localized prostate cancer: comparison of different techniques. Int J Radiat Oncol Biol Phys. 1993;25:359-371.
26. Leibel SA, Fuks Z, Zelefsky MJ, et al. Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer. Semin Oncol. 2003;30:596-615.
27. Jani AB. The effectiveness of combining hormone therapy and radiotherapy in the treatment of prostate cancer. Expert Opin Pharmacother. 2004;5:2469-2477.
28. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. East Norwalk, CT: Prentice Hall, 1990.
29. Radiation Therapy Oncology Group (RTOG). Toxicity Information. Sections 7-8: Acute and Late Radiation Morbidity Criteria) http://www.rtog.org/members/ toxicity/main.html.
30. Zavoina W, McKelvey RD. A statistical model for the analysis of ordinal level dependent variables. J Math Sociol. 1975;4:103-120.
31. Jani AB, Gratzle J. Late radiotherapy toxicity after prostate cancer treatment: influence of hormonal therapy. Urology. 2005;66:566-570.